Anteris Technologies Global Corp. (AVR)
| Market Cap | 178.68M |
| Revenue (ttm) | 2.14M |
| Net Income (ttm) | -84.32M |
| Shares Out | 41.20M |
| EPS (ttm) | -2.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 80,961 |
| Open | 4.540 |
| Previous Close | 4.540 |
| Day's Range | 4.540 - 4.775 |
| 52-Week Range | 2.340 - 8.790 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 16.50 (+253.32%) |
| Earnings Date | Nov 12, 2025 |
About AVR
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for s... [Read more]
Financial Performance
In 2024, AVR's revenue was $2.70 million, a decrease of -1.17% compared to the previous year's $2.74 million. Losses were -$76.29 million, 65.8% more than in 2023.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AVR stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 253.32% from the latest price.
News
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for th...
Anteris Announces Results for the Third Quarter of 2025
MINNEAPOLIS, Minn. and BRISBANE, Australia , Nov. 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company comm...
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart compa...
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed t...
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed ...
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed ...
Anteris Announces Results for the Second Quarter of 2025
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to...
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to...
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris ® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed...
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-year
Anteris Reports 2024 Financial Results and Provides Corporate Update
EAGAN, Minn. and BRISBANE, Australia, March 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed ...
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC” or “Anteris”) is pleased to announce the closing of its initial public offering of 14,800,000 shares of i...
Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC”) today announced the pricing of its initial public offering of 14,800,000 shares of its common stock (“Co...
Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering
BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. (“ATGC”) today announced that it has launched the roadshow for its proposed initial public offering of 14,800,000...
Cardiac device maker Anteris Technologies files for $75M IPO
Cardiac device maker Anteris Technologies Global (AVR) has filed to raise $75M through a U.S. initial public offering.
Australian medical device company Anteris Technologies Global files for a $75 million US IPO
Anteris Technologies Global, an Australia-based maker of artificial heart valves, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The company's shares are curren...
Anteris Technologies Global IPO Registration Document (S-1)
Anteris Technologies Global has filed to go public with an IPO on the NASDAQ.